JP Morgan Maintains Neutral on 10x Genomics, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Neutral 55.8%

Neg 0% Neu 55.8% Pos 0%

JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $17 to $20.